Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Curr Top Med Chem. 2024;24(1):60-73. doi: 10.2174/0115680266251803230925075508.
Over the centuries, influenza and its associated epidemics have been a serious public health problem. Although vaccination and medications (such as neuraminidase inhibitors) are the mainstay of pharmacological approaches to prevent and treat influenza, however, frequent mutations in the influenza genome often result in treatment failure and resistance to standard medications which limit their effectiveness. In recent years, green tea catechins have been evaluated as potential anti-influenza agents. Herein, in this review, we highlighted the effects and mechanisms underlying the inhibitory effects of epigallocatechin 3-gallate (EGCG), the most abundant ingredient in green tea, against different influenza viral infections, and their clinical benefits toward prevention and treatment. In addition, as the severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) causes the outbreak of COVID-19 pandemic, our review also delineates the current perspective on SARS-CoV-2 and future insights as to the potential application of EGCG on suppressing the flu-like symptoms caused by COVID-19.
几个世纪以来,流感及其相关的流行一直是一个严重的公共卫生问题。虽然疫苗接种和药物(如神经氨酸酶抑制剂)是预防和治疗流感的主要药理学方法,但流感基因组的频繁突变常常导致治疗失败和对标准药物的耐药性,从而限制了它们的有效性。近年来,绿茶儿茶素已被评估为有希望的抗流感药物。在本文综述中,我们强调了表没食子儿茶素没食子酸酯(EGCG)的作用及其抑制不同流感病毒感染的机制,及其在预防和治疗方面的临床益处。此外,由于严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)导致 COVID-19 大流行,我们的综述还阐述了 SARS-CoV-2 的当前观点以及对 EGCG 抑制 COVID-19 引起的类似流感症状的潜在应用的未来展望。